Huang Yixi, Wang Jiayi, Yang Wenbin, Hou Feifei, Feng Xiaodong
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Frontier Innovation Center for Dental Medicine Plus & Research Unit of Oral Carcinogenesis and Management & Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, Sichuan, China.
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Oral and Maxillofaical Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Infect Agent Cancer. 2025 Mar 11;20(1):17. doi: 10.1186/s13027-025-00641-7.
The increasing incidence and mortality rates of HPV-positive cancers, particularly HPV-positive head and neck cancer, in recent years have emphasized the pressing need for more efficacious treatment options. Recent studies have elucidated the molecular distinctions between HPV-positive and HPV-negative cancers, which are crucial for developing precise and effective therapeutic strategies. This review updates the most recent findings on the molecular variances between HPV-positive and HPV-negative cancers, evaluates current treatments for HPV-positive cancers, and summarizes emerging frontiers in HPV-targeted therapies aimed at developing more effective and precise interventions against these cancers.
近年来，人乳头瘤病毒（HPV）阳性癌症，尤其是HPV阳性头颈癌的发病率和死亡率不断上升，这凸显了对更有效治疗方案的迫切需求。最近的研究阐明了HPV阳性和HPV阴性癌症之间的分子差异，这对于制定精确有效的治疗策略至关重要。本综述更新了关于HPV阳性和HPV阴性癌症之间分子差异的最新发现，评估了HPV阳性癌症的当前治疗方法，并总结了以HPV为靶点的治疗领域的新进展，旨在开发针对这些癌症更有效、更精确的干预措施。
